Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Gains Distributors in China, India for ICEme Kits

NEW YORK (GenomeWeb) – Transgenomic said today that it has signed two new agreements with distributors in China and India for its ICEme mutation enrichment kits — with JoyingBio in China and Biotron Healthcare in India.

According to President and CEO Paul Kinnon, the two new distributors offer Transgenomic important access to rapidly expanding markets.

"We decided to work with these new distributors in response to the increasingly robust demand we are seeing in Asia for our ICEme Kits, which we believe reflects the exceptional accuracy, versatility, and ease of use of our unique ICP technology," he said.

Using multiplexed ICE COLD-PCR, the ICEme kits allow laboratories working with a variety of different existing platforms to conduct high-quality DNA mutation detection in cancer patients using tissue, plasma, blood, or other body fluid samples.

ICEme kits are customizable, and can be used with single mutations or in combination. The company's current menu includes about 20 clinically relevant, actionable mutations associated with cancers like colorectal, lung, breast, and melanoma.

The deals are not Transgenomic's first in Asia. It also made two other agreements for distribution of ICEme last year — one with Spectron Scientific in China and the other with Sowa Trading Company in Japan.

As of this August, the company also has a non-exclusive distribution agreement for the kits with VWR in North America.


The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more